Regulatory Approval

(Image: Getty/scanrail)

Scaling down: Clinical research shifts its focus

By Maggie Lynch

Smaller company’s last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from the need to scale infrastructure, says Tufts director.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers